Protara Therapeutics Inc
TARA3.095USD
+0.035+1.14%
Market hours （ET）Quotes delayed by 15 min
119.40MMarket Cap
LossP/E TTM
More Details of Protara Therapeutics Inc Company
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Company Info
Ticker SymbolTARA
Company nameProtara Therapeutics Inc
IPO dateOct 22, 2014
CEOMr. Jesse Shefferman
Number of employees28
Security typeOrdinary Share
Fiscal year-endOct 22
Address345 Park Avenue South
CityNEW YORK
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code10010
Phone16468440337
Websitehttps://protaratx.com/
Ticker SymbolTARA
IPO dateOct 22, 2014
CEOMr. Jesse Shefferman
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Luke M. Beshar, CPA
Mr. Luke M. Beshar, CPA
Independent Chairman of the Board
Independent Chairman of the Board
198.00K
--
Dr. Jacqueline Zummo, Ph.D.
Dr. Jacqueline Zummo, Ph.D.
Chief Scientific Operations Officer
Chief Scientific Operations Officer
52.40K
-9.50%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
51.00K
+64.52%
William Conkling
William Conkling
Chief Commercial Officer
Chief Commercial Officer
50.00K
--
Ms. Hannah Fry
Ms. Hannah Fry
Controller
Controller
36.81K
+23.38%
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Independent Director
Independent Director
33.00K
--
Mr. Gregory P. Sargen
Mr. Gregory P. Sargen
Independent Director
Independent Director
31.00K
--
Dr. Michael Edward (Mike) Solomon, Ph.D.
Dr. Michael Edward (Mike) Solomon, Ph.D.
Independent Director
Independent Director
26.50K
--
Mr. Patrick (Pat) Fabbio
Mr. Patrick (Pat) Fabbio
Chief Financial Officer
Chief Financial Officer
4.27K
-79.09%
Ms. Justine O'Malley
Ms. Justine O'Malley
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Luke M. Beshar, CPA
Mr. Luke M. Beshar, CPA
Independent Chairman of the Board
Independent Chairman of the Board
198.00K
--
Dr. Jacqueline Zummo, Ph.D.
Dr. Jacqueline Zummo, Ph.D.
Chief Scientific Operations Officer
Chief Scientific Operations Officer
52.40K
-9.50%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
51.00K
+64.52%
William Conkling
William Conkling
Chief Commercial Officer
Chief Commercial Officer
50.00K
--
Ms. Hannah Fry
Ms. Hannah Fry
Controller
Controller
36.81K
+23.38%
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Independent Director
Independent Director
33.00K
--
Revenue Breakdown
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
9.82%
RA Capital Management, LP
8.81%
Blackstone Alternative Asset Management, L.P.
4.52%
Opaleye Management Inc.
4.48%
Velan Capital Investment Management LP
4.32%
Other
68.04%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
9.82%
RA Capital Management, LP
8.81%
Blackstone Alternative Asset Management, L.P.
4.52%
Opaleye Management Inc.
4.48%
Velan Capital Investment Management LP
4.32%
Other
68.04%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
21.94%
Hedge Fund
20.37%
Investment Advisor
15.94%
Venture Capital
13.71%
Individual Investor
2.88%
Research Firm
2.69%
Pension Fund
0.19%
Bank and Trust
0.10%
Other
22.18%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
113
30.02M
77.80%
-5.36M
2025Q1
109
30.14M
79.11%
-5.49M
2024Q4
103
31.00M
91.11%
+17.03M
2024Q3
78
11.90M
57.00%
-1.22M
2024Q2
78
11.87M
56.87%
+435.17K
2024Q1
73
5.94M
51.57%
-1.39M
2023Q4
74
5.63M
49.24%
-1.76M
2023Q3
82
6.95M
61.22%
-1.14M
2023Q2
92
7.24M
64.00%
-2.26M
2023Q1
120
7.75M
68.57%
-3.28M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
3.79M
9.82%
--
--
Mar 31, 2025
RA Capital Management, LP
3.40M
8.81%
--
--
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
1.74M
4.52%
+64.04K
+3.81%
Mar 31, 2025
Opaleye Management Inc.
1.73M
4.48%
-95.00K
-5.21%
Mar 31, 2025
Velan Capital Investment Management LP
1.67M
4.32%
+88.80K
+5.62%
Mar 31, 2025
The Vanguard Group, Inc.
1.60M
4.15%
+243.34K
+17.90%
Mar 31, 2025
Sio Capital Management, LLC
1.51M
3.92%
+76.80K
+5.34%
Mar 31, 2025
Integral Health Asset Management, LLC
1.40M
3.63%
--
--
Mar 31, 2025
Acorn Capital Advisors, LLC
1.28M
3.32%
--
--
Mar 31, 2025
StemPoint Capital LP
1.19M
3.09%
+858.18K
+258.18%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
Avantis US Small Cap Equity ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
